Bae, SeungJin Professor
Pharmaceutical Sciences/Division of Pharmacy/Industrial Pharmaceutical Science
Prof. SeungJin Bae is a renowned expert in the area of Pharmacoeconomics and pricing & reimbursement of pharmaceuticals. She has earned her doctoral degree from Harvard School of Public Health, Department of Health Policy and Management. She is currently being involved with topics including value of new drugs, reimbursement poliicy for oncology drugs, and quality-adjusted life years. She has published more than 15 papers in the international journals, and co-authored textbook titled "Administrative and Managerial Pharmacy". She was also principal investigator of various policy reports published by the Health Insurance Review and Accessment Service.
- Pharmaceutical Science Building B #112
- 02-3277-3056
Research Record
- Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries BioDrugs, 2024, v.38 no.1, 133-144
- Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design Cancer Research and Treatment, 2024, v.56 no.4, 991-1013
- Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study BioDrugs, 2024, v.38 no.2, 301-311
- Corporate social responsibility of pharmaceutical industry in Korea FRONTIERS IN PHARMACOLOGY, 2022, v.13, 950669
- How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea Frontiers in Pharmacology, 2022, v.13, 884769
- Impact and challenges of enactment for advanced regenerative medicine in South Korea FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, v.10, 972865
- Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version Applied Health Economics and Health Policy, 2022, v.20 no.4, 467-477
- Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea International Journal of Environmental Research and Public Health, 2022, v.19 no.5, 2494
- The Impact of Payment Scheme Changes on Medication Adherence and Persistence of Patients Diagnosed with Depression in Korea International Journal of Environmental Research and Public Health, 2022, v.19 no.17, 11100
- The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS BMC Health Services Research, 2022, v.22 no.1, 900
- Computed tomographic measurements of the psoas muscle as a predictor of mortality in hip fracture patients: Muscle attenuation helps predict mortality in hip fracture patients Injury, 2021, v.52 no.6, 1456-1461
- Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future Current Medical Research and Opinion, 2021, v.37 no.9, 1529-1545
- How can we improve patients’ access to new drugs under uncertainties? : South Korea’s experience with risk sharing arrangements BMC Health Services Research, 2021, v.21 no.1, 967
- Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, v.18 no.8, 4106
- Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, v.21 no.4, 527-540
- Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2021, v.9, 737504
- Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, v.36 no.29, e191
- The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future FRONTIERS IN PUBLIC HEALTH, 2021, v.9, 671961
- Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, v.18 no.6, 3139
- A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients' Experience INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020 , 9412
- Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System CLINICAL THERAPEUTICS, 2020, v.42 no.7, 1222-1233
- Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea BMC PUBLIC HEALTH, 2020, v.20 no.1, 0
- Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate FRONTIERS IN PHARMACOLOGY, 2020, v.11, 232
- Me-too validation study for in vitro skin irritation test with a reconstructed human epidermis model, KeraSkin™ for OECD test guideline 439 Regulatory Toxicology and Pharmacology, 2020, v.117, 104725
- Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children International journal of environmental research and public health, 2020, v.17 no.12
- The Burden of Cervical Cancer in Korea: A Population-Based Study INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, v.17 no.17, 6308
- Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? Frontiers in Pharmacology, 2020, v.11, 970
- Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-US Free Trade Agreement in Korea INTERNATIONAL JOURNAL OF HEALTH SERVICES, 2019, v.49 no.2, 306-321
- Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea HEALTH POLICY, 2019, v.123 no.4, 388-392
- Evaluation of skin sensitization potential of chemicals by local lymph node assay using 5-bromo-2-deoxyuridine with flow cytometry Regulatory Toxicology and Pharmacology, 2019, v.107, 104401
- Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study BMJ OPEN, 2019, v.9 no.9, e030930
- Me-too validation study for in vitro eye irritation test with 3D-reconstructed human cornea epithelium, MCTT HCETM Toxicology in Vitro, 2019, v.55, 173-184
- Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study BMJ OPEN, 2019, v.9 no.3, e026603
- Statistical analysis of the reproducibility and predictive capacity of MCTT HCE™ eye irritation test, a me-too test method for OECD TG 492 Regulatory Toxicology and Pharmacology, 2019, v.107, 104430
- Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, v.41 no.6, 1434-1441
- Mental stress from animal experiments: A survey with Korean researchers Toxicological Research, 2018, v.34 no.1, 75-81
- Response to Letter to the Editor on our paper "Evaluation of radioisotopic and non-radioisotopic versions of local lymph node assays for subcategorization of skin sensitizers compliant to UN GHS rev 4" by Ha et al. (Submitted 25 Jun 2017) REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2018, v.94, 325-329
- Evaluation of radioisotopic and non-radioisotopic versions of local lymph node assays for subcategorization of skin sensitizers compliant to UN GHS rev 4 Regulatory Toxicology and Pharmacology, 2017, v.85, 124-131
- Modeling lifetime costs and health outcomes attributable to secondhand smoke exposure at home among Korean adult women BMJ Open, 2017, v.7 no.5
- Prevalidation trial for a novel in vitro eye irritation test using the reconstructed human cornea-like epithelial model, MCTT HCE™ Toxicology in Vitro, 2017, v.39, 58-67
- Real-world prescribing patterns of long-acting benzodiazepines for elderly Koreans in 2013 International Journal of Clinical Pharmacology and Therapeutics, 2017, v.55 no.6, 472-479
- Eight-year experience of using HTA in drug reimbursement: South Korea HEALTH POLICY, 2016, v.120 no.6, 612-620
- Exploration and comparison of in vitro eye irritation tests with the ISO standard in vivo rabbit test for the evaluation of the ocular irritancy of contact lenses TOXICOLOGY IN VITRO, 2016, v.37, 79-87
- FACTORS ASSOCIATED WITH POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY KOREANS IN AN OUTPATIENT SETTING: A POPULATION-BASED STUDY JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, v.64 no.9, E21-E23
- Factors associated with potentially inappropriate medication use in elderly Koreans in an outpatient setting: A population-based study Journal of the American Geriatrics Society, 2016, 26 July 2016
- Factors associated with the Career Preference of 6-Year Doctor of Pharmacy (Pharm.D) Students in Korea: a National Survey INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2016, v.50 no.3, 322-329
- Metabolomic analysis of amino acids and lipids in human hair altered by dyeing, perming and bleaching Experimental Dermatology, 2016, v.25 no.9
- Performance standard-based validation study for local lymph node assay: 5-bromo-2-deoxyuridine-flow cytometry method REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2016, v.80, 183-194
- Predictive capacity of a non-radioisotopic local lymph node assay using flow cytometry, LLNA: BrdU-FCM: Comparison of a cutoff approach and inferential statistics Journal of Pharmacological and Toxicological Methods, 2016, v.78, 76-84
- Appraisal of within- and between-laboratory reproducibility of non-radioisotopic local lymph node assay using flow cytometry, LLNA: BrdU-FCM: Comparison of OECD TG429 performance standard and statistical evaluation TOXICOLOGY LETTERS, 2015, v.234 no.3, 172-179
- Relationship of ceramide-, and free fatty acid-cholesterol ratios in the stratum corneum with skin barrier function of normal, atopic dermatitis lesional and non-lesional skins JOURNAL OF DERMATOLOGICAL SCIENCE, 2015, v.77 no.1, 71-74
- Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea HEALTH POLICY, 2015, v.119 no.5, 577-587
- 중증질환 치료제에 대한 급여정책을 둘러싼 윤리적 쟁점 고찰 보건경제와 정책연구, 2015, v.21 no.1, 125-148
- Analysis of statistical methods currently used in toxicology journals Toxicological Research, 2014, v.30 no.3, 185-191
- KeraSkin™-VM: A novel reconstructed human epidermis model for skin irritation tests Toxicology in Vitro, 2014, v.28 no.5, 742-750
- Sourcing Quality-of-Life Weights Obtained from Previous Studies: Theory and Reality in Korea PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2014, v.7 no.2, 141-150
- Suppression of skin inflammation in keratinocytes and acute/chronic disease models by caffeic acid phenethyl ester Archives of Dermatological Research, 2014, 12 December 2014
- 제약업계의 학사수준 신입인력 전공 선호도 연구 약 학 회 지, 2014, 제58권 6호, 397-404
- 한국, 호주, 캐나다, 영국의 항암제 및 희귀의약품의 접근성에 대한 고찰 보건경제와 정책연구, 2014, 제20권 2호, 1-20
- 주요국의 제네릭 의약품 활성화 정책 고찰과 시사점 보건행정학회지, 2013, v.23 no.3, 210-223
- [학술지논문] Self-testing strategy to eliminate Hepatitis C as per WHO’s goal: Analysis of disease burden and cost-effectiveness Clinical and molecular hepatology, 2025, v.10 no.2 , 1-10
- [학술지논문] Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries BIODRUGS, 2024, v.38 no.1 , 133-144
- [학술지논문] Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study BIODRUGS, 2024, v.38 no.2 , 301-311
- [학술지논문] Corporate social responsibility of pharmaceutical industry in Korea FRONTIERS IN PHARMACOLOGY, 2022, v.13 no.0 , 950669-950669
- [학술지논문] For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, v.19 no.7 , 4204-4204
- [학술지논문] How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea FRONTIERS IN PHARMACOLOGY, 2022, v.13 no.0 , 884769-884769
- [학술지논문] Impact and challenges of enactment for advanced regenerative medicine in South Korea Frontiers in Bioengineering and Biotechnology, 2022, v.10 no.0 , 972865-972865
- [학술지논문] Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, v.20 no.4 , 467-477
- [학술지논문] Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, v.19 no.19 , 1-6
- [학술지논문] Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, v.19 no.5 , 2494-2494
- [학술지논문] The Impact of Payment Scheme Changes on Medication Adherence and Persistence of Patients Diagnosed with Depression in Korea INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, v.19 no.17 , 11100-11100
- [학술지논문] The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS BMC HEALTH SERVICES RESEARCH, 2022, v.22 no.1 , 900-900
- [학술지논문] Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future CURRENT MEDICAL RESEARCH AND OPINION, 2021, v.37 no.9 , 1529-1545
- [학술지논문] How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements BMC HEALTH SERVICES RESEARCH, 2021, v.21 no.1 , 967-967
- [학술지논문] Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, v.18 no.8 , 4106-4106
- [학술지논문] Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, v.21 no.1 , 1-14
- [학술지논문] Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement Frontiers in Bioengineering and Biotechnology, 2021, v.9 no.0 , 737504-737504
- [학술지논문] The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future FRONTIERS IN PUBLIC HEALTH, 2021, v.9 no.0 , 671961-671961
- [학술지논문] Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, v.18 no.6 , 3139-3139
- [학술지논문] A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients' Experience INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, v.17 no.24 , 9412-9412
- [학술지논문] Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System CLINICAL THERAPEUTICS, 2020, v.42 no.7 , 1222-1233
- [학술지논문] Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea BMC PUBLIC HEALTH, 2020, v.20 no.1 , 1-11
- [학술지논문] Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate FRONTIERS IN PHARMACOLOGY, 2020, v.11 no.0 , 232-232
- [학술지논문] Me-too validation study for in vitro skin irritation test with a reconstructed human epidermis model, KeraSkin (TM) for OECD test guideline 439 REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, v.117 no.0 , 104725-104725
- [학술지논문] Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, v.17 no.12 , 4496-4496
- [학술지논문] The Burden of Cervical Cancer in Korea: A Population-Based Study INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, v.17 no.17 , 6308-6308
- [학술지논문] Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? FRONTIERS IN PHARMACOLOGY, 2020, v.11 no.0 , 970-970
Courses
-
2025-1st
-
Pharmacoeconomics
- Subject No 37147Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Tue 4~4 (POSCO)
-
Industrial Pharmacy & Administrative Pharmacy Practice
- Subject No 37153Class No 02
- 6Year ( 2.5Credit , 160Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmaceutical Statistics 강의 계획서 상세보기
- Subject No 38922Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 3~3 (PHM-A404)
- Major Requisite,Language Changed
-
Introduction to Pharmaceutical Research
- Subject No 38940Class No 01
- 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A404)
- Major Requisite
-
Pharmaceutical Statistics
- Subject No 39026Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 5~5 (POSCO462)
- Major Requisite,Language Changed
-
Principles of Pharmaceutical Economics and Policy
- Subject No G17175Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-)
-
Social Pharmacy
- Subject No BR699Class No 01
- Year ( 3Credit , 3Hour) Wed 8~9 (PHM-)
-
Social Pharmacy
- Subject No CP530Class No 01
- Year ( 3Credit , 3Hour) Wed 8~9 (PHM-)
-
-
2024-2nd
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Wed 5~5 (PHM-A400)
- Major Requisite
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A400)
- Major Requisite
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 03
- 5Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A400)
- Major Requisite
-
Pharmacy Administration
- Subject No 37124Class No 01
- 4Year ( 1.5Credit , 1.5Hour) Thu 3~3 (PHM-A404)
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmacy Ethics
- Subject No 38932Class No 01
- 2Year ( 1.5Credit , 1.5Hour)
- Major Requisite
-
Pharmacy Ethics
- Subject No 39037Class No 01
- 2Year ( 1.5Credit , 1.5Hour)
- Major Requisite
-
Project Analysis Ⅰ
- Subject No G16659Class No 01
- Year ( 3Credit , 3Hour) Fri 1~2 (PHM-)
- Classroom Changed
-
Methods in Economic Evaluation in Pharmaceuticals Ⅰ
- Subject No G16816Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-)
- Class Hour Changed
-
Methods in Economic Evaluation
- Subject No G18086Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-)
- Class Hour Changed
-
-
2024-1st
-
Pharmacoeconomics
- Subject No 37147Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Tue 4~4 (PHM-A404)
-
Industrial Pharmacy & Administrative Pharmacy Practice
- Subject No 37153Class No 02
- 6Year ( 2.5Credit , 160Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmaceutical Statistics
- Subject No 39026Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 5~5 (POSCO551)
- Major Requisite
-
Pharmaceutical Statistics Computer Lab 강의 계획서 상세보기
- Subject No 39027Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 6~6 (POSCO159)
- Major Requisite
-
Introduction to Pharmaceutical Research
- Subject No 39045Class No 01
- 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A100-1)
-
Seminar for Pharmaceutical Sciences Ⅲ 강의 계획서 상세보기
- Subject No G16849Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A-400)
-
Methods in Economic Evaluation in Pharmaceuticals Ⅱ
- Subject No G17177Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-)
-
Seminar for Pharmaceutical Sciences Ⅲ 강의 계획서 상세보기
- Subject No G18240Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A-400)
-
-
2023-2nd
-
Pharmaceutical Jurisprudence 강의 계획서 상세보기
- Subject No 22491Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Wed 5~5 (PHM-A104)
- Major Requisite
-
Pharmaceutical Jurisprudence 강의 계획서 상세보기
- Subject No 22491Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Thu 5~5 (POSCO462)
- Major Requisite
-
Pharmaceutical Jurisprudence 강의 계획서 상세보기
- Subject No 22491Class No 03
- 5Year ( 1.5Credit , 1.5Hour) Thu 6~6 (POSCO462)
- Major Requisite
-
Pharmaceutical Jurisprudence 강의 계획서 상세보기
- Subject No 22491Class No 04
- 5Year ( 1.5Credit , 1.5Hour) Thu 6~6 (POSCO462)
- Major Requisite
-
Pharmacy Administration 강의 계획서 상세보기
- Subject No 37124Class No 01
- 4Year ( 1.5Credit , 1.5Hour) Thu 3~3 (PHM-A404)
-
Advanced Pharmacy Practice and Research I 강의 계획서 상세보기
- Subject No 37154Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Advanced Pharmacy Practice and Research Ⅱ 강의 계획서 상세보기
- Subject No 37155Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Advanced Pharmacy Practice and Research Ⅲ 강의 계획서 상세보기
- Subject No 37156Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmacy ethics 강의 계획서 상세보기
- Subject No 38932Class No 01
- 2Year ( 1.5Credit , 1.5Hour)
- Major Requisite
-
Pharmacy ethics 강의 계획서 상세보기
- Subject No 39037Class No 01
- 2Year ( 1.5Credit , 1.5Hour)
- Major Requisite
-
Methods in Economic Evaluation in Pharmaceuticals I
- Subject No G16816Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-)
-
-
2023-1st
-
Pharmaceutical statistics
- Subject No 37108Class No 01
- 3Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A404)
-
Pharmacoeconomics
- Subject No 37147Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Tue 5~5 (PHM-A404)
-
Pharmacoeconomics
- Subject No 37147Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Tue 5~5 (PHM-A404)
-
Industrial Pharmacy & Administrative Pharmacy Practice 강의 계획서 상세보기
- Subject No 37153Class No 02
- 6Year ( 2.5Credit , 160Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmaceutical statistics 강의 계획서 상세보기
- Subject No 38922Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Thu 4~4 (PHM-A404)
- Major Requisite
-
Pharmaceutical statistics 강의 계획서 상세보기
- Subject No 39026Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 5~5 (POSCO359)
- Major Requisite
-
Pharmaceutical Statistics computer lab 강의 계획서 상세보기
- Subject No 39027Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Wed 6~6 (POSCO159)
- Major Requisite
-
Introduction to Pharmaceutical Research 강의 계획서 상세보기
- Subject No 39045Class No 01
- 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-)
-
Principles of Pharmaceutical Economics and Policy
- Subject No G17175Class No 01
- Year ( 3Credit , 3Hour) Tue 6~7 (PHM-A-204)
-
-
2022-2nd
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Wed 5~5 (PHM-A400)
- Major Requisite
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Thu 3~3 (PHM-A400)
- Major Requisite
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 03
- 5Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A404)
- Major Requisite
-
Pharmaceutical Jurisprudence
- Subject No 22491Class No 04
- 5Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A404)
- Major Requisite
-
Pharmacy Administration
- Subject No 37124Class No 01
- 4Year ( 1.5Credit , 1.5Hour) Thu 2~2 (PHM-A404)
-
Pharmacy Administration
- Subject No 37124Class No 02
- 4Year ( 1.5Credit , 1.5Hour) Thu 2~2 (PHM-A404)
-
Advanced Pharmacy Practice and Research Ⅱ
- Subject No 37155Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Lab rotation Ⅰ
- Subject No 38927Class No 01
- 1Year ( 1.5Credit , 0Hour) Thu 7~7
-
Lab rotation Ⅰ
- Subject No 38927Class No 02
- 1Year ( 1.5Credit Thu 7~7
-
Lab rotation Ⅰ
- Subject No 39032Class No 01
- 1Year ( 1.5Credit , 0Hour) Thu 7~7
-
Methods in Economic Evaluation in Pharmaceuticals I
- Subject No G16816Class No 01
- Year ( 3Credit , 3Hour) Wed 8~9 (PHM-)
-
-
2022-1st
-
Pharmaceutical statistics
- Subject No 37108Class No 01
- 3Year ( 1.5Credit , 1.5Hour) Thu 6~6
- Language Changed
-
Pharmacoeconomics
- Subject No 37147Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Fri 3~3 (PHM-A404)
- Language Changed
-
Pharmacoeconomics
- Subject No 37147Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Fri 3~3 (PHM-A404)
- Language Changed
-
Industrial Pharmacy & Administrative Pharmacy Practice
- Subject No 37153Class No 02
- 6Year ( 2.5Credit , 160Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Pharmaceutical statistics
- Subject No 38922Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Thu 5~5
- Major Requisite,Language Changed
-
Pharmaceutical statistics
- Subject No 39026Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Fri 5~5 (POSCO552)
- Major Requisite,Language Changed
-
Pharmaceutical Statistics computer lab
- Subject No 39027Class No 01
- 1Year ( 1.5Credit , 1.5Hour) Fri 6~6 (POSCO159)
- Major Requisite
-
Principles of Pharmaceutical Economics and Policy
- Subject No G17175Class No 01
- Year ( 3Credit , 3Hour) Fri 8~9 (-)
-
Social Pharmacy
- Subject No CP530Class No 01
- Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
-